Kroger Will Sell Over 700 Stores

Competition is heating up in the grocery store industry. Performance expectations are on the rise, and grocery stores in the U.S. are reevaluating how they do business in an effort to stay relevant.
One major chain, The Kroger Company, has made a big decision toward that end, according to a recent Nasdaq report. The company has made a deal to sell its convenience stores so that it may direct more energy toward its core operations.
In a reported $2.15 billion deal, the chain will sell over 700 stores—those operating as Turkey Hill, Loaf ‘N Jug, Kwik Shop, Tom Thumb, and Quik Stop—to an England-based convenience store company, the EG Group. It will hold onto its Turkey Hill Dairy stores and its fuel centers, however.
With unpredictable food prices and extreme competition in the industry, the decision makes sense, especially in a climate characterized by bold moves, such as the recent Amazon deal to take over Whole Foods. Kroger reportedly plans to use the sales profits to expand its store base, roll out new items, rejuvenate its digital coupon system, and develop its online order/store-pickup service. The company will also rev up its Scan, Bag, Pay & Go and Self-CheckOut programs, now piloted at 20 stores, in its nearly 400 locations in 2018.
These moves will likely pay off big for the company, jumpstarting its performance and driving stock prices, in an environment that demands that grocers go big or go home.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More